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Abstract
Recently, our group has developed a therapeutic hypertensive
vaccine against angiotensin (Ang) II type 1 receptor (AT1R)
named ATRQβ-001. To explore its potential effectiveness on
streptozotocin-induced diabetic nephropathy, male Sprague
Dawley rats were randomly divided into two groups: a control
and a diabetic model. After 1 week, the diabetic rats were
divided into four subgroups (each with 15 rats) for 14-week
treatments with saline, olmesartan, ATRQβ-001, and Qβ
virus-like particle (VLP), respectively. In addition to lower
blood pressure, ATRQβ-001 vaccination ameliorated bio-
chemical parameter changes of renal dysfunction, mesangial
expansion, and fibrosis through inhibiting oxidative stress,
macrophage infiltration, and proinflammatory factor expres-
sion. Furthermore, ATRQβ-001 vaccination suppressed renal
Ang II-AT1R activation and abrogated the downregulation of
angiotensin-converting enzyme 2-Ang (1–7), similar to
olmesartan treatment, while no obvious feedback activation
of circulating or local renin-angiotensin system (RAS) was
only observed in vaccine group. In rat mesangial cells, the
anti-ATR-001 antibody inhibited high glucose-induced
transforming growth factor-β1 (TGF)-β1/Smad3 signal path-
way. Additionally, no significant immune-mediated damage
was detected in vaccinated animals. In conclusion, the
ATRQβ-001 vaccine ameliorated streptozotocin-induced dia-
betic renal injury via modulating two RAS axes and inhibiting
TGF-β1/Smad3 signal pathway, providing a novel, safe, and
promising method to treat diabetic nephropathy.
Key messages
& Overactivation of RAS plays a crucial role in the develop-
ment of the DN.
& Our aim was to verify the effectiveness of ATRQβ-001
vaccine in STZ-induced DN.
& The ATRQβ-001 modulated two RAS axes and inhibited
TGF-β1/Smad3 signal pathway.
& The vaccine therapy may provide a novel, safe, and prom-
ising method to treat DN.
Keywords Angiotensin receptor . Streptozotocin .
Renin-angiotensin system . Diabetic nephropathy . Vaccine
Introduction
Diabetic nephropathy (DN) is the most common cause of end-
stage renal diseases, responsible for over 40 % of all cases in
the USA, and this number is likely to increase unabated [1].
Overactivation of the renin-angiotensin system (RAS) plays a
crucial role in the development of the disease [2]. Current
treatment, aimed at slowing progression, concentrates on
two inter-related therapeutic strategies: blood pressure reduc-
tion and blockade of the RAS [3–5]. Such treatments have
been shown to reduce the functional changes seen in DN
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and also to attenuate the structural abnormalities that charac-
terize this disease [6–8]. At present, blockade of the RAS is
achieved by two major drug classes: angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor
blockers (ARBs), agents that also lower systemic blood pres-
sure [9]. However, they are not completely effective in
preventing or reversing the progress of DN, in part due to a
compensatory increase in plasma renin activity (PRA) or Ang
II [10]. Current therapies are insufficient, necessitating the
search for new therapeutic strategies in DN.
Recently, we developed a therapeutic hypertensive vaccine
ATRQβ-001, a peptide (ATR-001) derived from human Ang
II receptor type 1 (AT1R) conjugated with Qβ bacteriophage
virus-like particles, which decreased the blood pressure of
hypertensive animals effectively through diminishing the
pressure response and inhibiting signal transduction initiated
by Ang II with no obvious feedback activation of circulating
or local RAS [11]. In our previous study, we demonstrated that
an epitope from the rat AT1R, designated as ATR12181, could
decrease SBP of spontaneously hypertensive rats (SHRs) and
provide excellent protections in target organs [12]. Following
our work, Hiroshi Itoh and his colleagues emphasized vacci-
nation against AT1R for the prevention of L-NAME-induced
nephropathy in SHRs, not only for the attenuation of hyper-
tension [13]. Ang II and other components of RAS also have a
central role in the pathogenesis and progression of diabetic
renal injuries. Accordingly, this study was designed to explore
the possibility of the ATRQβ-001 vaccine in ameliorating of
experimental DN and the potential mechanisms. The study
was undertaken in Sprague Dawley rats treated with
streptozotocin that developed renal injury similarities to hu-
man DN [14].
Methods
Detailed methods are available in the Online Supplement.
Animals
Male Sprague Dawley rats weighing 200–250 g were pur-
chased from the experimental animal research center (Hubei
Province, China). All animals were kept in the pathogen-free
room in the experimental animal center (Tongji Medical
College of Huazhong University of Science and Technology,
Wuhan, China), and all experiments were carried out in accor-
dance with guidelines for the Care and Use of Laboratory
Animals (Science and Technology Department of Hubei
Province, China, 2005). Experimental diabetes was induced
by intraperitoneal injection of the β cell toxin streptozocin
(60 mg/kg) dissolved in fresh sodium citrate buffer (pH 4.5)
following an overnight fast. Animals with plasma glucose
concentrations in excess of 16.7mmol/l, 1 week postinduction
of diabetes, were included in the study. Sham-injected control
animals (sodium citrate buffer, pH 4.5) were followed concur-
rently. Diabetes rats were then randomized into four groups
(n=15), receiving one of the following treatments: (1) DN
group: equal volume saline injection subcutaneously (s.c);
(2) OM group: olmesartan, 5 mg/kg/day via oral gavage; (3)
ATRQβ-001group: the ATRQβ-001 vaccine, which was im-
munized s.c 400 μg on days 0, 14, and 21, formulated in
aluminum hydroxide gel; (4) virus-like particle (VLP) group:
400μg Qβ VLP injected as group 3. Each week, rats were
weighed and their blood glucose levels were measured.
ATR-001-specific antibody titers were detected in every
2 weeks. Every 4 weeks, systolic blood pressure (SBP) was
determined in preheated conscious rats via tail-cuff plethys-
mography using a non-invasive blood pressure controller and
PowerLab system.
Plasma renin activity, Ang II, and Ang (1–7) concentration
measurement
The rats were decapitated between 9 am and 12 am. Blood
samples were collected and divided into two parts: one was
mixed with the enzyme inhibitor mixture (1 ml blood in 50 μl
inhibitor mixture including 20 μl 0.3 mol/l EDTA, 10 μl
0.32 mol/l dimercaprol, and 20 μl 0.34 mol/l 8-OH-
quinoline sulfate) for PRA and Ang II concentration measure-
ment by radioimmunoassay (RIA) according to the assay kit
instruction (NIBT, Beijing); the other was used for biochem-
ical experiments. For tissue Ang II and Ang (1–7) measure-
ment, immediately after harvesting and weighing, the kidney
cortex were immersed in ice-cold methanol, minced, and ho-
mogenized with tissue homogenizers. The homogenates were
centrifuged (4000 rpm, 4 °C, 15 min), and the supernatants
were dried overnight in a vacuum centrifuge. The dried resi-
due was reconstituted in 1 ml RIA buffer and then was sub-
jected to HPLC to separate Ang II from other substances. The
tissue Ang II concentration was detected according to the as-
say kit instruction (NIBT, Beijing), and Ang (1–7) was mea-
sured by HPLC.
Biochemical measurement
The plasma samples were used for the measurement of glu-
cose, lipid level, creatinine (Cr), and blood urea nitrogen
(BUN). Urine samples were collected using metabolic cages,
and the supernatant was used for examination of the 24-h
urinary protein.
Histopathology
Parts of fresh left renal cortex were immediately fixed in
0.25 % glutaraldehyde for transmission electron microscopy
(TEM) . The o the r pa r t s we r e f i x ed w i t h 4 %
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paraformaldehyde overnight, embedded in paraffin for histo-
pathology. Sections were stained with hematoxylin-eosin
(H&E), Masson’s trichrome, and periodic acid-Schiff (PAS).
Frozen sections were stained with dihydroethidium (DHE).
Immunohistochemistry
Immumohistochemical staining was performed to detect the
expression of TGF-β1 (1:100, Everest Biotech) and macro-
phages (CD68, 1:100, AbD Serotec) in glomeruli.
Immunofluorescence
Immunofluorescence staining of nephrin and podocin expres-
sion was performed on the paraffin sections of kidneys using
monoclonal anti-nephrin (1:200, Abcam) and anti-podocin
antibodies (1:200, Abcam).
Cell culture and treatment
Rat mesangial cells (RMCs) were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10 % fetal bo-
vine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin
at 37 °C in 95 % air and 5 % CO2. Cells plated on 60-mm
dishes were cultured to 80 % confluence and divided into five
groups: control group, in which cells were incubated in
5 mmol/l D-glucose DMEM, and 20 mmol/l D-mannitol
was added to the medium in order to take into the account of
the effect of high osmolarity in other cell groups; HG group, in
which cells were stimulated with a high concentration of glu-
cose (25 mmol/l) only for 24 h; Los group, in which cells were
pretreated with 10−6 mol/l losartan for 1 h; anti-ATR-001
group, in which cells were pretreated with anti-ATR-001 for
1 h; anti-NATR-001 group, in which cells were pretreated
with anti-NATR-001 for 1 h. All cells except control group
received stimulation with a high concentration of glucose
(25 mmol/l) for 24 h after treatment. Cell protein and messen-
ger RNA (mRNA) were extracted for Western blot and qRT-
PCR analysis.
Statistical analysis
Data were shown as the mean±SEM. Statistical analyses of
the data were performed with one-way ANOVA using
SPSS18.0. P<0.05 was considered statistically significant.
Results
Animal characteristics
In comparison with control animals, diabetic rats had signifi-
cantly reduced body weight, which was unaffected by treat-
ment. The ratio of kidney weight/body weight was increased,
while ATRQβ-001 vaccine and olmesartan treatments de-
creased the level. Blood glucose and lipid levels were elevated
to a similar extent in all diabetic rat groups, irrespective of
treatment (Table 1). No evidence of skin damages at the site
of subcutaneous injection was noted in vaccine-treated ani-
mals. Less activities and poorer hair were shown in diabetic
rats, but the reactivity was the same as normal rats.
ATRQβ-001 vaccination effectively reduced blood
pressure and reversed biochemical parameters of renal
dysfunction in STZ-induced diabetic rats
To examine antibody production, wemeasured the amounts of
anti-ATR-001 antibodies produced in response to vaccination
Table 1 Animal characteristics
Con DN VLP OM ATRQβ-001
Body weight (g) 359±12.69 173.3±9.78* 169.2±8.47* 216±18.68* 184.7±9.7*
Kidney weight (g) 1.19±0.03 1.15±0.03 1.14±0.02 1.36±0.08 1.11±0.04
KW/BW (%) 0.33±0.01 0.67±0.02* 0.69±0.02* 0.58±0.02*#& 0.63±0.03*#
Blood glucose (mmol/l) 7.8±1.84 31.6±3.11* 34.0±1.84* 30.4±1.30* 30.2±2.55*
TC (mmol/l) 1.49±0.1 2.48±0.56* 2.6±0.63* 2.33±0.16* 2.58±0.34*
TG (mmol/l) 0.85±0.19 2.53±0.28* 2.32±0.17* 2.19±0.37* 2.31±0.28*
LDL-C (mmol/l) 2.87±0.44 4.48±0.65* 4.21±0.71* 4.09±0.75* 4.01±0.91*
HDL-C (mmol/l) 0.77±0.04 0.81±0.13 0.79±0.19 0.96±0.11 0.98±0.05
Values are mean±SEM
KW/BW kidney weight/body weight, TC total cholesterol, TG total triglyceride, LDL-C low-density lipoprotein
cholesterol, HDL-C high-density lipoprotein cholesterol, Con control group, DN diabetes with saline treatment,
VLP diabetes with Qβ VLP treatment, OM diabetes with olmsartan treatment, ATRQβ-001 diabetes with the
ATRQβ-001 vaccine treatment
*P<0.05 vs. Con; #P<0.05 vs. DN; &P<0.05 vs. VLP
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with ATRQβ-001. After the second injection of the vaccine,
the ATR-001-specific antibody titer was 1:10,000 to 1:30,000,
and it rose after the third injection, then peaked on day 42
(1:40,000) and gradually decreased thereafter (Fig. 1a). To
investigate the efficacy in blood pressure, systolic blood pres-
sure (SBP) levels were measured by the tail-cuff method. Over
the course of the study, SBP was elevated in DN compared to
normal rats, while rats immunized with the ATRQβ-001 vac-
cine were decreased compared to the VLP group, with a max-
imum decrease of 19.4 mmHg (129.9+2.9 vs. 149.3+
3.6 mmHg, P<0.01, Fig. 1b).
To evaluate the biochemical parameters of renal func-
tion, 24 h urine volume, and total protein excretion, blood
urea nitrogen and creatinine were measured. Diabetic rats
exhibited higher levels in all these parameters. ATRQβ-
001 vaccine and olmesartan-treated rats significantly re-
duced these parameters compared to DN and VLP groups,
and no significant differences were between these two
groups (Fig. 1c–f).
ATRQβ-001 vaccination prevented podocyte injury
and loss as well as mesangial expansion
To confirm the effect of vaccination, we evaluated renal path-
ological changes. Podocytes form the filtration slit dia-
phragms that prevents the escape of plasma protein from the
glomerular circulation. The disruption of podocytes contrib-
utes to proteinuria and further development of glomerular
sclerosis [15]. Reduced nephrin and podocin immunostaining
in glomeruli were showed in diabetic rats, and ATRQβ-001
vaccination prevented the reduction (Fig. 2).
In addition to podocyte injury, glomerular mesangial ex-
pansion is also a hallmark of DN. Extracellular matrix depo-
sition was detected by periodic acid-Schiff staining, and glo-
merular sclerosis index (GSI) was calculated. Compared with
DN and VLP groups, GSI was significantly decreased in
ATRQβ-001-vaccinated group, similar with olmesartan-
treated group, which was also confirmed by transmission elec-
tron microscopy (TEM) (Fig. 2).
Fig. 1 Antibody titers, systolic
blood pressure, and biochemical
parameters. a Diabetic rats were
immunized on days 0, 14, 21, and
70, and the ATR-001-specific
antibody titers were screened on
days 21, 28, 42, 56, 70, 77, 91,
and 98. b Systolic blood pressure
on weeks 14; *P<0.05 vs. the
control group; #P<0.05 vs. DN
group; &P<0.05 vs. VLP group.
c 24 h urine volume; *P<0.05 vs.
the control group at the same time
point. d 24 h urine protein;
*P<0.05 vs. the control group at
the same time point; #P<0.05 vs.
DN group at the same time point;
&P<0.05 vs. VLP group at the
same time point. e Plasma
creatinine level (n=10). f Blood
urea nitrogen level (n=10).
*P<0.05 vs. control group;
#P<0.05 vs. DN group;
&P<0.05 vs. VLP group
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ATRQβ-001 vaccination ameliorated renal fibrosis
and inflammation
To further investigate the mechanisms, renal fibrosis and in-
flammation parameters were measured. The extent of intersti-
tial expansion was quantified by Masson’s trichrome-stained
sections. The interstitial expansive index was higher in DN
and VLP groups, and ATRQβ-001 vaccination blocked the
increase (Fig. 3). Glomerular and interstitial inflammation
was quantified by the cell numbers of macrophages stained
positively with CD68 antibody, and ATRQβ-001 vaccination
successfully prevented the increased inflammation (Fig. 3).
Besides, we detected transforming growth factor-β1
(TGF-β1) expression and reactive oxygen species, which
was also decreased by ATRQβ-001 vaccine treatment.
Further, the mRNA expressions of profibrotic and proinflam-
matory factors in kidney cortex were measured. As shown in
Fig. 3f, g, the increased mRNA levels in these factors were
significantly suppressed by ATRQβ-001 vaccination. There
were no significant differences between ATRQβ-001- and
olmesartan-treated groups.
ATRQβ-001 vaccination suppressed renal Ang II-AT1R
activation and abrogated the downregulation
of ACE2-Ang (1–7) with no feedback of RAS
To determine whether blockade of AT1R lead to feed-
back activation of circulating RAS, we detected the
Fig. 2 ATRQβ-001 vaccination prevented podocyte injury and loss as
well as mesangial expansion. a Representative micrographs of nephrin
and podocin expression, periodic acid-Schiff (PAS) staining (400×), and
transmission electron microscopy (TEM). TEM showed the glomerular
basement membrane and the mesangial area. b Quantitative analysis of
nephrin expression. c Quantitative analysis of podocin expression. d
Quantitative analysis of glomerular sclerosis index based on PAS
staining. e Quantitative analysis of glomerular basement membrane
thickness. *P<0.05 vs. control group; #P<0.05 vs. DN group;
&P<0.05 vs. VLP group
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PRA and Ang II concentration. The PRA in ATRQβ-
001 vaccinated group was 13 660±2904 pmol/h/l,
which had no significant difference with VLP group
(21,450±2851 pmol/h/l, P=0.48). However, a distinct
increase was observed in olmesartan group (43 040±8
157 pmol/h/l, P=0.005; Fig. 4a). Similarly, the plasma
concentration of Ang II in olmesartan group was higher
than VLP group (567.3±80.7 vs. 291.8±29.16 pmol/l,
P=0.02), whereas no significant difference was ob-
served between VLP and vaccine groups (291.8±29.16
vs. 288.7±19.33, P=0.53; Fig. 4b). To further examine
the local RAS, kidney Ang II concentration was
Fig. 3 ATRQβ-001 vaccination ameliorated renal fibrosis and
inflammation. a Representative staining of Masson’s trichrome, DHE
(200×), macrophages, and TGF-β1 (400×). b Quantitative analysis of
interstitial fibrosis. c Quantitative analysis of DHE fluorescence. d
Quantitative analysis of glomerular and interstitial macrophage
numbers. e Quantitative analysis of TGF-β1 expression. f The levels of
profibrotic factor mRNA expression measured by quantitative real-time
PCR (n=10). g The levels of proinflammatory factor mRNA expression
measured by quantitative real-time PCR (n=10). *P<0.05 vs. control
group; #P<0.05 vs. DN group; &P<0.05 vs. VLP group
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measured. The concentration of Ang II in kidneys was
lower in olmsartan- and vaccine-treated groups com-
pared to DN and VLP groups (Fig. 4d). To investigate
whether the protection effect was a result of increase
Ang (1–7) activation with simultaneous Ang II suppres-
sion, we subsequently measured plasma and kidney Ang
(1–7). The decline of Ang (1–7) in diabetic rats was
improved in ATRQβ-001 vaccine and olmesartan-
treated groups (Fig. 4c, e).
Activation of RAS in streptozotocin (STZ)-induced dia-
betic kidneys was further confirmed by Western blot and
quantitative real-time PCR (Fig. 5). The mRNA expression
of kidney renin in olmesartan group was obviously higher
than VLP group (P<0.001), while no difference was found
between ATRQβ-001 vaccine and VLP groups (Fig. 5g).
ACE and AT1R expressions were increased in diabetic rats,
and both ATRQβ-001 vaccine and olmesartan groups atten-
uated the increasing expressions. ACE2-Ang (1–7)-mas ax-
is counteract Ang II-mediated effects in various organs, in-
cluding the kidneys, and we observed reduced expression of
ACE2-Ang (1–7)-mas in the diabetic kidneys. ATRQβ-001
vaccine and olmesartan displayed upregulation of ACE2-
Ang (1–7)-mas expression compared with VLP group.
Further, we also detected the downstream signal transduc-
tion and the activation of ERK1/2, and p38 MAPK phos-
phorylation was inhibited by ATRQβ-001 vaccination, sim-
ilar to olmesartan treatment (Fig. 5e–f).
Anti-ATR-001 inhibited the TGF-β1/Smad3 signal
pathway and expression of collagen IV and fibronectin
in rat mesangial cells
To further explore the mechanisms, cell experiment was un-
dertaken by anti-ATR-001 stimulation. Glomerular mesangial
cells are believed to be responsible for overproduction of
ECM proteins in various pathologic conditions, and TGF-β1
has been proposed to play an important role. The TGF-β1/
Smad3 signal pathway regulates the hypertrophic and
prosclerotic changes in diabetic renal injury [16]. Anti-ATR-
001 and losartan treatment significantly decreased the expres-
sion of TGF-β1 and the phosphorylation levels of Smad3 in
RMCs stimulated by high glucose. Additionally, we examined
the expression of collagen IV and fibronectin, which showed
similar change as TGF-β1 (Fig. 6).
No imumune-mediated injury was observed in vaccinated
animals
For safety consideration, normal SD rats were immu-
nized with the ATRQβ-001 vaccine, and the histological
changes of kidney were observed by light microscopy
and TEM. No evidence of skin damages at the site of
subcutaneous injection was noted in vaccine-treated an-
imals. Compared with control group, no obvious cell
proliferation and pathological changes in the mesangial
Fig. 4 Circulating or local RAS were not activated in ATRQβ-001-
vaccinated diabetic rats. a Plasma renin activity. b Plasma angiotensin
II concentration. c Plasma angiotensin (1–7) concentration. d kidney
angiotensin II concentration. e Kidney angiotensin (1–7) concentration.
N=10. *P<0.05 vs. control group; #P<0.05 vs. DN group; &P<0.05 vs.
VLP group; §P<0.05 vs. OM group
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area were shown in vaccine group. Also, TEM demon-
strated that no immune complexes were observed in the
basement membrane, and the structure of the glomerulus
was intact (Fig. 7).
Discussion
In this study, we demonstrated for the first time that in a rat
model of DN, a vaccine targeting AT1R named ATRQβ-001
Fig. 5 Effect of ATRQβ-001 vaccination on the RAS components,
ERK1/2, and P38 MAPK in STZ-induced diabetic kidneys.
Representative Western blots (lower panel) showing specific bands for
a ACE, b ACE2, c AT1R, d Mas, e P-ERK1/2, and f P-p38 and
quantitative analysis were presented on upper panel (n=10). g The
relative mRNA expression of angiotensingen, renin, (pro)renin receptor,
ACE, ACE2, AT1R, AT2R, and Mas detected by quantitative real-time
PCR (n=10). *P<0.05 vs. control group; #P<0.05 vs. DN group;
&P<0.05 vs. VLP group
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attenuated the progression of the disease, as exhibited by re-
duction of biochemical parameters of renal dysfunction and
amelioration of renal pathological changes.
The rat DN model was induced by an intraperitoneal injec-
tion of STZ that has been widely used to create diabetes models
in rodents with pathological features similar to human diabetic
nephropathy [14]. The nephropathy subcommittee of the
Animal Models of Diabetic Complications Consortium
(AMDCC) has published the following validation criteria for
rodent models of DN based on the clinical and pathological
features of human DN: (1) >50 % decrease in renal function,
(2) >10-fold increase in albuminuria, and (3) pathological fea-
tures including advanced mesangial matrix expansion (±nod-
ules), thickening of the glomerular basement membrane, arte-
riolar hyalinosis, and tubulointerstitial fibrosis [17]. An ideal
model of DN would display all of these criteria; however, no
current model entirely satisfies them. That is the limitation in
animal experiments. As the rodent models share many similar-
ities with human disease, we cannot ignore the potential thera-
peutic value of the vaccine in the treatment of human diseases.
Our results showed that rats presented severe hyperglycemia
and renal dysfunction manifested as increased plasma creati-
nine level, BUN, 24 h urinary volume, and protein excretion,
indicating that a DN animal model was successfully
established. The ratio of kidney weight/body weight in diabetic
groups was significantly increased compared with that in con-
trol group, substantial to the presence of renal hypertrophy in
diabetic rats. During the course of the study, systolic blood
pressure was elevated in diabetic rats, notwithstanding the lim-
itations of tail-cuff sphygmomanometry, ATRQβ-001 vaccina-
tion lowered blood pressure (BP) smoothly, and olmesartan
decreased to a greater extend. It is worth noting that our animal
Fig. 6 Anti-ATR-001 inhibited the TGF-β1/Smad3 signal pathway and
expression of collagen IVand fibronectin in rat mesangial cells. As shown
on a and b, anti-ATR-001 specifically bound to AT1R in rat mesangial
cells (RMCs). Representative Western blots (lower panel) showing
specific bands for c P-ERK1/2, d TGF-β1, e Smad3, and quantitative
analysis were presented on upper panel. The relative expression of
TGF-β1 and collagen I and IV mRNAwere shown on f, g, and h. Con
control, HG high glucose (25 mmol/l), Los losartan treatment, Anti-ATR
anti-ATR-001 treatment, NATR anti-NATR-001 treatment (n=5).
*P<0.05 vs. con; #P<0.05 vs. HG
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experiments showed many times that the antihypertensive ef-
fect of ATRQβ-001 vaccine was dependent on the baseline of
the BP level and exhibited no decreasing effect in normotensive
rats. Oppositely, ARBs decreased BP irrespective of the basic
level and had an increase risk of hypotension. Therefore,
ATRQβ-001 vaccine may be more practical in diseases where
the BP was not very high, such as DN.
Glomerular mesangial matrix expansion, renal fibrosis, and
inflammation are typical pathological features of DN.
ATRQβ-001 vaccination ameliorated these morphologic
changes of renal injury as well as decreased expression of
profibrotic and proinflammatory factors. To further confirm
the effects, RMCs were used to investigate the mechanism
in vitro. The anti-ATR-001 antibody treatment effectively
inhibited high glucose-induced extracellular signal-regulated
kinase phosphorylation and TGF-β1/Smad3 signal pathway.
These results strengthened the renoprotection of ATRQβ-001
vaccination in addition to the antihypertensive effect. The in-
hibition of oxidative stress and macrophage infiltration as well
as proinflammatory factor expression may contribute to the
amelioration of renal pathological changes.
Furthermore, compared with the obvious RAS feedback of
ARBs, circulating or local RAS were not elevated in diabetes
animals immunized with ATRQβ-001 vaccine. Nevertheless,
kidney Ang II concentration and AT1R expression were de-
creased in both groups. The recent development of ACE2-
Ang (1–7)-mas concept has provided new insights into the
effects of Ang II in animal experimental models. This novel
concept states that RAS has two axes: the ACE-Ang II-AT1R
axis and ACE2-Ang (1–7)-mas axis. The former axis induces
vasoconstriction, proliferation, and proinflammatory func-
tions through Ang II, and the latter axis counteract the effects
of the former axis through the major heptapeptide effector
Ang (1–7) [18, 19]. ACE2 cleaves Ang II to produce abundant
levels of Ang (1–7) in the proximal tubule, which produces
vasodilation and antiproliferative, natriretic, and diuretic ef-
fects [20]. Despite its significant role, the exact role of
ACE2 and Ang (1–7) in kidney disease is not clearly under-
stood. It has been reported that inhibition of ACE2 function
accelerates diabetic injury and human recombinant ACE2 re-
duces the progression [21, 22]. Moreover, Ang (1–7) attenu-
ates the progression of diabetic nephropathy in animal models
[23, 24]. Our study showed a downregulation of ACE2-Ang
(1–7)-mas axis in diabetic rats, and the beneficial effects of
ATRQβ-001 vaccine and olmesartan treatment may partly
due to the upregulation of this axis. Although the exact mech-
anism of how these two axes counteract with each other re-
mains unknown, we can conclude that the vaccine regulates
the two RAS axes, not only inhibiting AT1R overactivation.
Safety considerations are paramount when developing any
vaccine but are particularly important when targeting a condi-
tion for which many safe and effective alternative therapies
are available. Four key factors define the safety of therapeutic
vaccine: (1) the targeted molecule, (2) the reversible of anti-
body response, (3) antibody-dependent cell-mediated cytotox-
icity (ADCC) and complement-mediated cytotoxicity, and (4)
Fig. 7 No imumune-mediated
injury was observed in vaccinated
animals. aRepresentative staining
of hematoxylin-eosin (H&E),
Masson’s trichrome, and periodic
acid-Schiff (PAS) and
transmission electron microscopy
(TEM). b Normal SD rats were
immunized on days 0 and 14, and
the ATR-001-specific antibody
titers were screened on days 21,
28, 42, 56, 77, 97, 120, and 150
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activation of T cells against self-molecules [25]. Combined
with our previous studies, vaccination-targeted AT1R showed
no immune-mediated injuries [11, 12] and was also confirmed
in this study. The antibody response was reversible as the
possibility of halting antibody production. For ADCC and
complement-mediated cytotoxicity, there are still several con-
troversies in terms of its onset and regulation. Nevertheless,
the potential effects caused by the vaccine needed further in-
vestigation. As the target peptide of the vaccine was only eight
amino acids in length, then it was smaller than the minimal
size of a T cell epitope and therefore should not be able to
induce a T cell response [26]. Several studies had estimated
that vaccines comprising self-molecules coupled to VLPs
present optical candidates capable of achieving efficacious
antibody levels while fulfilling the necessary safety criteria
[27, 28]. Examples like the Ang II vaccine CYT-006-
AngQb, which showed effectively reduced BP without any
uncontrolled immune stimulation in both animals and patients
[29, 30]. Similar to the composition, the kidney damage
caused by immune complexes was not detected and no visible
pathological changes were observed by light microscopy and
TEM in ATRQβ-001-vaccinated animals. From the results
above, the ATRQβ-001 vaccine was found to be basically
safe, although further assessments are needed to confirm this
conclusion.
Compared with chemical drugs, the vaccine therapy has
potentially superior advantages. The half-life of the anti-
ATR-001 antibody was 14.4 days [11], longer than any other
chemical drugs presently used. No obvious feedback activa-
tion of circulating or local RAS was observed. Additionally,
long-term treatment of chronic diseases is costly, tedious, and
at the population level rather unsuccessful. Monoclonal anti-
bodies specific for host proteins have proven to be highly
effective, and the movement from the passive administration
of monoclonal antibodies to active vaccination against self-
molecular could provide affordable medicines and broader
patient acceptance and compliance. The question today in
many patient populations is not whether to block the RAS
but rather how best to inhibit its activity. From a theoretical
perspective, vaccination has much to recommend it as a strat-
egy. ATRQβ-001 vaccine modulates two major axes of RAS
and ameliorates STZ-induced diabetic injury with no obvious
immune-mediated damages, providing a promising therapeu-
tic method to treat diabetic nephropathy.
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